Avita Medical has announced that Woody Fralin, one of its directors, has acquired £15,700 worth of common stock in the company. The news comes as no surprise given the company's strong financial performance in recent years. Avita Medical is a pioneering medical technology firm specialising in regenerative and skin repair treatments. Its products are used by hospitals and clinics around the world to treat severe burns and other complex wounds.
The share price of Avita Medical has not been affected by Mr Fralin's investment, with the company's value remaining steady on the UK stock market. This move is seen as a vote of confidence in the organisation's future prospects by its key stakeholders.
Avita Medical has received significant recognition for its innovative products and commitment to improving patient outcomes. The company was awarded the 2020 iAwards Gold Medal for its pioneering work in regenerative medicine. Its products are also used in several clinical trials, including those being conducted at major UK hospitals such as St Thomas' Hospital in London.
Avita Medical's shares are listed on the FTSE AIM market and are available to trade on several online platforms, including Hargreaves Lansdown and Interactive Investor. The company's financial results for 2022 will be announced later this year, providing further insight into its performance.